U.S. FDA Approves IBRANCE (palbociclib) for the Treatment of Men with HR+, HER2- Metastatic Breast Cancer
NEW YORK--(BUSINESS WIRE)--Apr 4, 2019--Pfizer (NYSE:PFE) today announced that the U.S. Food and Drug Administration (FDA) approved a supplemental New Drug Application (sNDA) to ex…
